In the safety set , we recorded no between-group difference in the number of patients who had adverse events ( indacaterol @ -LSB- @ % -RSB- of @ patients vs tiotropium @ -LSB- @ % -RSB- of @ patients ) or serious adverse events ( indacaterol , @ -LSB- @ % -RSB- of @ patients vs tiotropium , @ -LSB- @ % -RSB- of @ patients ) .